<?xml version="1.0" encoding="UTF-8"?>
<p>The Vaccae™ vaccine is a heat-killed preparation of 
 <italic>Mycobacterium vaccae</italic>, an NTM closely related to 
 <italic>M. obuense</italic>
 <sup>
  <xref rid="ref-55" ref-type="bibr">55</xref>
 </sup>
 <italic>.</italic> Vaccae™ has been licensed in China as adjunctive immunotherapy for drug treatment of active TB. A pooled analysis of data from trials of the 
 <italic>M. vaccae</italic> vaccine suggested some potential utility when used as an immunotherapeutic adjunct to drug treatment of active pulmonary TB 
 <sup>
  <xref rid="ref-56" ref-type="bibr">56</xref>
 </sup>. In 2012, the Chinese government approved the initiation of a clinical trial to test the candidate vaccine for prevention of the occurrence of tuberculosis in subjects with LTBI. A 10,000-person, placebo-controlled phase 3 study involving a 6-dose vaccination regimen was initiated (NCT01979900). Retention rates in the trial were high, and more than 100 cases of TB occurred during the study. The efficacy and safety data from this completed study have not yet been released.
</p>
